Serum concentrations of GDF-15 were found to increase continuously during the 15-month follow-up of breast cancer patients treated with doxorubicin and trastuzumab, and increased GDF-15 levels were significantly associated with an increased risk of LVEF reduction (59). This evidence concerns the gene GDF15 and breast carcinoma.